Stocks · News reference
CNBC Halftime Report Final Trades: Airbnb, Gilead Sciences, KLA, Snowflake
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 11, 2026, 5:01 PM
- Checked
- Aug 11, 2026, 5:01 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Bernstein Maintains Outperform on Airbnb, Raises Price Target to $217
Bernstein analyst Richard Clarke maintains Airbnb (NASDAQ:ABNB) with a Outperform and raises the price target from $168 to $217.
Read original at benzingaAirbnb shares are trading higher after Evercore ISI Group maintained its Outperform rating on the stock and raised its price target from $190 to $200.
Read original at benzingaEvercore ISI Group Maintains Outperform on Airbnb, Raises Price Target to $200
Evercore ISI Group analyst Mark Mahaney maintains Airbnb (NASDAQ:ABNB) with a Outperform and raises the price target from $190 to $200.
Read original at benzingaGilead’s Trodelvy-Keytruda Combo Gets EU Approval for Metastatic Breast Cancer
Read original at benzingaInvesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up?
The Invesco Pharmaceuticals ETF (PJP) offers concentrated exposure to 29 pharma giants with better historical returns and lower volatility, while the Invesco Nasdaq Biotechnology ETF (IBBQ) provides broader diversification across 251 holdings at a lower expense ratio of 0.19% versus 0.57%. Despite IBBQ's cost advantage, PJP is recommended as the better buy due to its significantly larger asset base ($512.6M vs $81M), which addresses liquidity concerns.
Read original at the-motley-fool